BridgeMD
EValuating the Effect of periopeRaTIve sodium-Glucose cOtransporter 2 inhibitors on cardiac surgery associated acute kidney injury: the VERTIGO study
EU CTIS ID: 2024-519997-37-00
What this study is testing
The primary aim of the VERTIGO trial is to evaluate whether once daily perioperative empagliflozin reduces the incidence of acute kidney injury, compared with placebo, in patients requiring elective cardiac surgery with extracorporeal circulation.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1) ≥18 years of age; 2) Requiring elective cardiac surgery with ECC; 3) Able to understand the aim of the study and to provide written informed consent
You likely can't join if
- 1) Emergent surgery; 2) Endocarditis; 3) Patients awaiting heart transplantation; 4) Planned use of intra-aortic balloon pump; 5) Type 1 diabetes; 6) Chronic kidney disease with eGFR <30 mL/min/1.73 m2; 7) Severe liver dysfunction (ALT or AST >3 times above the upper limit of normality); 8) Active cancer; 9) Active treatment with any SGLT2i; 10) Known allergy to empagliflozin, any other SGLT2i or any of its excipients; 11) Solid organ transplant recipients; 12) Pregnant or lactating women; 13) Patients who are participating in another clinical trial
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.